Apex Biotechnology

Apex Biotechnology FCF Margin

The Free Cash Flow Margin of Apex Biotechnology (1733.TW) as of Nov 22, 2026 is 7.65 %. In the previous year, Free Cash Flow Margin was 16.14 % — a change of -52.59% (lower).

FCF Margin

7.65 %

YoY

-52.59%

Last updated:

Free Cash Flow Margin of Apex Biotechnology is 2025 7.65 % . Free Cash Flow Margin of Apex Biotechnology was 2024 16.14 % . It decreases by -52.59% lower compared to the previous year.

The Apex Biotechnology FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-0.38 TWD
Jan 1, 2019
18.46 TWD
Jan 1, 2020
11.58 TWD
Jan 1, 2021
7.21 TWD
Jan 1, 2022
-0.61 TWD
Jan 1, 2023
12.25 TWD
Jan 1, 2024
16.14 TWD
Jan 1, 2025
7.65 TWD
The Apex Biotechnology FCF Margin history
YEARFCF MarginYoY
7.65 %-52.59%
16.14 %+31.77%
12.25 %-2,124.15%
-0.61 %-108.40%
7.21 %-37.76%
11.58 %-37.26%
18.46 %-4,985.78%
-0.38 %-115.39%
2.45 %-83.33%
14.72 %-38.94%
24.11 %+113.35%
11.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apex Biotechnology Stock analysis

What does Apex Biotechnology do? Apex Biotechnology Corp is a Taiwan-based company specializing in the development of innovative biotechnology products. The company was founded in 2002 and offers a wide range of products and services to its customers. Apex Biotechnology Corp began with the production of specialty chemicals and enzymes for research and development purposes. Over the years, the company has expanded its business and focused on the development of diagnostic products, dietary supplements, and pharmaceutical products. The company's business model focuses on the development and marketing of biotechnology products. Apex Biotechnology Corp has established advanced research centers and works closely with research institutions and pharmaceutical companies worldwide to develop innovative solutions. The company operates in various sectors, including diagnostics, dietary supplements, and pharmaceuticals. It offers a diverse range of products, including enzyme immunoassays, lateral flow tests, dietary supplements, and pharmaceuticals. Apex Biotechnology Corp has built strong relationships with research institutions and pharmaceutical companies and has successfully marketed its products internationally. Apex Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apex Biotechnology stock

Free Cash Flow Margin of Apex Biotechnology is 7.65 % in 2025.

Free Cash Flow Margin of Apex Biotechnology changed from 16.14 % to 7.65 %, representing a -52.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Apex Biotechnology since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Apex Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Apex Biotechnology

All Key Metrics — Apex Biotechnology